Sobers guided for Q4 2025 revenue in the range of $76 million to $78 million, representing 14% year-over-year growth at the midpoint, with gross margin in the range of 78% to 79% and adjusted EBITDA ...
Pharma marketers enter 2026 asking where DTC fits in the DTP era. That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient (DTP) programs. In the last few months ...
GoodRx projects Pharma Direct revenue to grow at least 30% year-over-year in 2026. Management anticipates continued acceleration in condition-specific subscriptions launched in late 2025, with weight ...
CEO James Reinhart highlighted "the third quarter was our strongest year-over-year growth in nearly 4 years and the fourth quarter in a row of accelerating growth." He reported revenue growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results